Forsidebilde av showet Therapeutic Momentum

Therapeutic Momentum

Podkast av Therapeutic Momentum

engelsk

Business

Tidsbegrenset tilbud

2 Måneder for 19 kr

Deretter 99 kr / MånedAvslutt når som helst.

  • 20 timer lydbøker i måneden
  • Eksklusive podkaster
  • Gratis podkaster
Kom i gang

Les mer Therapeutic Momentum

The Therapeutic Momentum podcast series illuminates the inspiring personal stories, touchstone moments, and transformational events that fuel the relentless pursuit of life-changing treatments. It reveals the intricate tapestry of experiences that drive people in the biomedical field who share the collective goal of improving patient outcomes. We hope to offer listeners a multifaceted perspective on the diverse talent and backgrounds of people working towards better health and hope for patients.

Alle episoder

8 Episoder

episode Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal cover

Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal

In this episode I am joined by Kate Haviland, who most recently served as President and CEO of Blueprint Medicines, guiding it from a clinical-stage company through a fully integrated commercial business and ultimately through its roughly $9.5 billion acquisition by Sanofi in 2025. Over a more than twenty-year career spanning Genzyme, PTC Therapeutics, Sarepta, Idera, and Blueprint, Kate has built a reputation for bridging rigorous science with sharp business instincts, equally fluent in the lab and the boardroom. She studied biochemistry and economics at Wesleyan, earned her MBA at Harvard Business School, and today serves as Board Chair of both Fulcrum Therapeutics and GC Therapeutics, as a director at Bicara and Avalyn, and on the board of BIO. This episode was recorded in 2025

16. mai 2026 - 53 min
episode AI + Life Sciences: Why the Future Needs Both Human Brains and Wet Labs cover

AI + Life Sciences: Why the Future Needs Both Human Brains and Wet Labs

In this episode, I speak with Sam Scarpino, Director of AI and Life Sciences at Northeastern University's Institute for Experiential AI and Professor of Public Health and Health Sciences. With a background spanning evolutionary biology, pandemic response during H1N1, and pathogen surveillance at the Rockefeller Foundation, Sam offers a distinctive perspective on artificial intelligence in the life sciences. We discuss the fundamental limitations of AI in biological systems, the irreplaceable role of wet lab experimentation, and how human-AI collaboration can address challenges from rural oncology access to rare disease drug development. Sam also shares his views on why current debates around AGI distract from the urgent work of building responsible AI tools today.

11. april 2026 - 57 min
episode Mathai Mammen - Motivated by Math, Medicine & Memories cover

Mathai Mammen - Motivated by Math, Medicine & Memories

Mathai Mammen is a world-renowned innovator in drug discovery, development, and team- and company-building responsible for creating 13 transformational medicines from discovery through commercial launch and more than 25 other potential medicines that have achieved clinical proof-of-concept, many of these practice-changing. Mathai is the CEO, President and Chairman of Cambridge-based Parabilis Medicines, a clinical-stage biopharmaceutical company advancing a new category of peptide therapeutics for people affected by cancer and other severe diseases. Previously Mathai was Executive Vice President of Pharmaceuticals, R&D at Johnson & Johnson, one of the largest R&D organizations in the world. Prior to that Mathai was the leader of much of the research at Merck including Oncology, Immunology and Cardiovascular Disease. He began his career as head of R&D at Theravance, Inc., a company he co-founded out of graduate school based on his work at Harvard University with Dr. George Whitesides, which split to form Theravance Biopharma and Innoviva. Mathai holds an M.D. from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.

20. juli 2025 - 1 h 8 min
Enkelt å finne frem nye favoritter og lett å navigere seg gjennom innholdet i appen
Enkelt å finne frem nye favoritter og lett å navigere seg gjennom innholdet i appen
Liker at det er både Podcaster (godt utvalg) og lydbøker i samme app, pluss at man kan holde Podcaster og lydbøker atskilt i biblioteket.
Bra app. Oversiktlig og ryddig. MYE bra innhold⭐️⭐️⭐️

Velg abonnementet ditt

Mest populær

Tidsbegrenset tilbud

Premium

20 timer lydbøker

  • Eksklusive podkaster

  • Ingen annonser i Podimo shows

  • Avslutt når som helst

2 Måneder for 19 kr
Deretter 99 kr / Måned

Kom i gang

Premium Plus

100 timer lydbøker

  • Eksklusive podkaster

  • Ingen annonser i Podimo shows

  • Avslutt når som helst

Prøv gratis i 14 dager
Deretter 169 kr / måned

Prøv gratis

Bare på Podimo

Populære lydbøker

Ofte stilte spørsmål

Flere spørsmål og svar
Kom i gang

2 Måneder for 19 kr. Deretter 99 kr / Måned. Avslutt når som helst.